By using a variety of pharmaceutical assays, we were able to demonstrate the superior anti-leukemic effect of volasertib in infant in contrast to adult leukemia; we revealed a higher PLK-1 expression in our infant MLLr model and commercially available cell lines (THP-1, SEM). This evidence concerns the gene PLK1 and leukemia.